What are the possible causes of concurrent hypercholesterolemia and low testosterone in an adult male?

Concurrent Hypercholesterolemia and Low Testosterone: Pathophysiology and Clinical Approach

The coexistence of elevated cholesterol and persistently low testosterone in adult males is most commonly explained by obesity-mediated functional hypogonadism, where increased adipose tissue aromatizes testosterone to estradiol, suppressing pituitary luteinizing hormone secretion, while simultaneously causing dyslipidemia—making weight loss the primary therapeutic intervention rather than immediate testosterone replacement. 1

Understanding the Bidirectional Relationship

Obesity as the Central Mechanism

Obesity is the major confounder linking hypercholesterolemia and low testosterone. 2 The pathophysiology operates through multiple interconnected pathways:

• Aromatization pathway: Excess adipose tissue contains high aromatase activity, converting testosterone to estradiol. This elevated estradiol provides negative feedback to the hypothalamus and pituitary, suppressing LH secretion and subsequently reducing testicular testosterone production. 1

• Sex hormone-binding globulin (SHBG) suppression: Obesity decreases SHBG concentrations, which paradoxically lowers total testosterone measurements even when free testosterone may be normal or only mildly reduced. 1, 2

• Lipid metabolism disruption: The same metabolic dysfunction causing obesity drives dyslipidemia through insulin resistance, increased hepatic VLDL production, and impaired lipoprotein clearance.

Emerging Lipid-Testosterone Associations

Recent evidence demonstrates specific cholesterol markers correlate with testosterone deficiency:

• Remnant cholesterol (RC) shows direct correlation with low testosterone risk, with each unit increase in RC associated with 2% higher odds of testosterone deficiency. 3

• Non-HDL-C to HDL-C ratio (NHHR) demonstrates linear inverse relationship with testosterone levels, with highest quartile showing 54.98 ng/dL lower testosterone compared to lowest quartile. 4

• RC/HDL-C ratio provides superior discriminatory ability for testosterone deficiency (AUC 0.647) compared to individual lipid parameters. 5

These associations are partially mediated through BMI and insulin resistance (HOMA-IR), confirming obesity as the mechanistic link. 3

Diagnostic Evaluation Algorithm

Step 1: Confirm True Hypogonadism

Measure morning (7-10 AM) fasting total testosterone on at least two separate occasions. 2, 6 Hypogonadism is confirmed when testosterone is consistently <264-300 ng/dL. 6

Critical caveat: In obese men, low total testosterone due to decreased SHBG may not reflect true androgen deficiency.

Step 2: Assess Free Testosterone

In men with obesity, diabetes, or metabolic syndrome, calculated free testosterone is essential. 2, 1, 2 Use equilibrium dialysis or calculations incorporating total testosterone, SHBG, and albumin. 2

• If free testosterone is normal despite low total testosterone: This represents SHBG-mediated artifact, not true hypogonadism
• If free testosterone is frankly low: Proceed with further evaluation

Step 3: Distinguish Primary vs. Secondary Hypogonadism

Measure LH and FSH to categorize: 1, 6

• Low/inappropriately normal LH + low testosterone = Secondary (hypothalamic-pituitary) hypogonadism
• Elevated LH + low testosterone = Primary (testicular) hypogonadism

Step 4: Identify Reversible Causes

For secondary hypogonadism, systematically evaluate:

• Medications: Opioids, glucocorticoids, anabolic steroids, checkpoint inhibitors, hyperprolactinemia-inducing drugs 7, 6
• Chronic illness: Diabetes, metabolic syndrome, chronic organ failure, HIV 8, 7
• Obesity: BMI ≥30 is the most common reversible cause 6
• Structural lesions: If LH/FSH disproportionately low, measure prolactin and consider pituitary imaging 1, 7

Treatment Algorithm

First-Line: Address Underlying Causes

For obesity-induced functional hypogonadism, weight loss is the primary treatment, not testosterone replacement. 6

• Weight loss ≥5% significantly increases serum testosterone and improves sexual function, physical function, and libido 6
• Discontinue causative medications when possible
• Optimize management of diabetes and metabolic syndrome

Second-Line: Testosterone Replacement Criteria

Consider testosterone therapy only when: 9, 10

1. Consistently low testosterone (confirmed on ≥2 morning samples)
2. Symptomatic hypogonadism (decreased libido, erectile dysfunction, reduced sexual activity)
3. Permanent hypogonadism or inability to address reversible causes
4. After explicit discussion of uncertain long-term risks and benefits

Do NOT initiate testosterone for: 9

• Energy, vitality, or physical function improvement (conditional recommendation, low-certainty evidence)
• Cognitive enhancement
• General "anti-aging" purposes in older men with low-normal testosterone

Testosterone Formulation Selection

When initiating therapy, prefer intramuscular over transdermal formulations due to considerably lower costs with similar efficacy and safety profiles. 9 However, individualize based on:

• Intramuscular (enanthate/cypionate): Cost-effective, but may cause mood/libido fluctuations
• Transdermal gels: More stable levels, but risk of transfer to contacts and variable absorption
• Patches: Stable delivery, but skin irritation common

Monitoring Protocol

Reassess at 12 months and periodically thereafter. 9

Discontinue testosterone if no improvement in sexual function after 12 months. 9

Monitor during treatment:

• Testosterone levels (target mid-normal range)
• Hematocrit (risk of erythrocytosis, especially with transdermal therapy) 7
• Prostate-specific antigen in men ≥40 years
• Lipid profile (testosterone may improve but monitor cholesterol concurrently)

Addressing the Cholesterol Component

Concurrent Lipid Management

Treat dyslipidemia according to cardiovascular risk, independent of testosterone status. The presence of low testosterone does not alter standard lipid management guidelines. 11

Important consideration: Testosterone replacement may modestly improve lipid profiles (increased HDL, decreased triglycerides, variable LDL effects), but this should not be the primary indication for therapy. 10

Monitoring Lipid-Testosterone Interactions

Given emerging evidence of lipid markers predicting testosterone deficiency 3, 4, 12, 5, consider:

• Screening testosterone in men with markedly elevated remnant cholesterol or NHHR
• Monitoring lipid profiles in men with diagnosed hypogonadism for cardiovascular risk stratification

Common Pitfalls to Avoid

1. Treating low total testosterone without assessing free testosterone in obese men – This leads to unnecessary testosterone replacement when SHBG suppression is the sole cause

2. Initiating testosterone without confirming permanent hypogonadism – Functional hypogonadism from obesity or medications is potentially reversible

3. Using testosterone as primary treatment for obesity-related hypogonadism – Weight loss is more effective and addresses the root cause

4. Prescribing testosterone for non-sexual symptoms – Evidence does not support use for energy, cognition, or general vitality 9

5. Failing to distinguish primary from secondary hypogonadism – This distinction has fertility implications and may reveal treatable pituitary pathology

6. Continuing ineffective testosterone therapy – Reassess at 12 months and discontinue if no symptomatic benefit 9